Review
. 2022 Mar; 14(6):.
doi: 10.3390/cancers14061580.

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

Megan M Y Hong 1 Saman Maleki Vareki 1 
Affiliations
  • PMID: 35326731
  •     154 References

Abstract

Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) is an immune checkpoint molecule highly expressed on regulatory T-cells (Tregs) that can inhibit the activation of effector T-cells. Anti-CTLA-4 therapy can confer long-lasting clinical benefits in cancer patients as a single agent or in combination with other immunotherapy agents. However, patient response rates to anti-CTLA-4 are relatively low, and a high percentage of patients experience severe immune-related adverse events. Clinical use of anti-CTLA-4 has regained interest in recent years; however, the mechanism(s) of anti-CTLA-4 is not well understood. Although activating T-cells is regarded as the primary anti-tumor mechanism of anti-CTLA-4 therapies, mounting evidence in the literature suggests targeting intra-tumoral Tregs as the primary mechanism of action of these agents. Tregs in the tumor microenvironment can suppress the host anti-tumor immune responses through several cell contact-dependent and -independent mechanisms. Anti-CTLA-4 therapy can enhance the priming of T-cells by blockading CD80/86-CTLA-4 interactions or depleting Tregs through antibody-dependent cellular cytotoxicity and phagocytosis. This review will discuss proposed fundamental mechanisms of anti-CTLA-4 therapy, novel uses of anti-CTLA-4 in cancer treatment and approaches to improve the therapeutic efficacy of anti-CTLA-4.

Keywords: ADCC/P; CD28 costimulation; CTLA-4; FOXP3; Tregs; anti-CTLA-4; immunotherapy; ipilimumab.

Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery.
Kenta Narumi, Reina Miyakawa, +7 authors, Kazunori Aoki.
Sci Rep, 2019 Apr 05; 9(1). PMID: 30944344    Free PMC article.
A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury.
Rita Simone, Renata Brizzolara, +7 authors, Daniele Saverino.
Int Immunol, 2009 Jul 25; 21(9). PMID: 19625381
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Xuexiang Du, Fei Tang, +14 authors, Yang Liu.
Cell Res, 2018 Feb 24; 28(4). PMID: 29472691    Free PMC article.
Highly Cited.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Molecular mechanisms of treg-mediated T cell suppression.
Angelika Schmidt, Nina Oberle, Peter H Krammer.
Front Immunol, 2012 May 09; 3. PMID: 22566933    Free PMC article.
Highly Cited.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, +18 authors, Gérard Zalcman.
Lancet, 2021 Jan 25; 397(10272). PMID: 33485464
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity.
Duncan Howie, Stephen Paul Cobbold, +10 authors, Herman Waldmann.
JCI Insight, 2017 Feb 15; 2(3). PMID: 28194435    Free PMC article.
TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis.
Yasmina Laouar, Terrence Town, +4 authors, Richard A Flavell.
Proc Natl Acad Sci U S A, 2008 Aug 02; 105(31). PMID: 18669656    Free PMC article.
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Daniel J Olson, Zeynep Eroglu, +17 authors, Jason J Luke.
J Clin Oncol, 2021 May 05; 39(24). PMID: 33945288    Free PMC article.
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.
Roberta Zappasodi, Inna Serganova, +21 authors, Taha Merghoub.
Nature, 2021 Feb 16; 591(7851). PMID: 33588426    Free PMC article.
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.
Ahmad A Tarhini, Haris Zahoor, +4 authors, John M Kirkwood.
J Immunother Cancer, 2015 Sep 18; 3. PMID: 26380086    Free PMC article.
Highly Cited.
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Antoni Ribas, Begoña Comin-Anduix, +9 authors, Alistair J Cochran.
Clin Cancer Res, 2009 Jan 02; 15(1). PMID: 19118070
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro.
Sandra Rosskopf, Judith Leitner, Gerhard J Zlabinger, Peter Steinberger.
Cancer Immunol Immunother, 2019 Jul 25; 68(8). PMID: 31332464    Free PMC article.
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid.
McLane J Watson, Paolo D A Vignali, +14 authors, Greg M Delgoffe.
Nature, 2021 Feb 17; 591(7851). PMID: 33589820    Free PMC article.
Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients.
Songbing He, Min Fei, +4 authors, Dechun Li.
Int J Mol Sci, 2011 Dec 17; 12(11). PMID: 22174607    Free PMC article.
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.
Ye Zheng, Steven Z Josefowicz, +3 authors, Alexander Y Rudensky.
Nature, 2007 Jan 24; 445(7130). PMID: 17237761
Highly Cited.
Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL.
Dolgor Baatar, Purevdorj Olkhanud, +3 authors, Arya Biragyn.
J Immunol, 2007 Apr 04; 178(8). PMID: 17404270    Free PMC article.
Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
K Vandenborre, S W Van Gool, +3 authors, P Vandenberghe.
Immunology, 1999 Dec 03; 98(3). PMID: 10583602    Free PMC article.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Luis Paz-Ares, Tudor-Eliade Ciuleanu, +24 authors, Martin Reck.
Lancet Oncol, 2021 Jan 22; 22(2). PMID: 33476593
Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity.
Hao Shi, Hongbo Chi.
Front Immunol, 2020 Jan 11; 10. PMID: 31921097    Free PMC article.
Review.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3.
Yong Zheng, Claire N Manzotti, +4 authors, David M Sansom.
J Immunol, 2008 Jul 22; 181(3). PMID: 18641304    Free PMC article.
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J Shimizu, S Yamazaki, S Sakaguchi.
J Immunol, 1999 Nov 24; 163(10). PMID: 10553041
Highly Cited.
CTLA-4-Ig regulates tryptophan catabolism in vivo.
Ursula Grohmann, Ciriana Orabona, +8 authors, Paolo Puccetti.
Nat Immunol, 2002 Oct 09; 3(11). PMID: 12368911
Highly Cited.
Phenotypical characterization of regulatory T cells in humans and rodents.
A L Rodríguez-Perea, E D Arcia, C M Rueda, P A Velilla.
Clin Exp Immunol, 2016 Apr 29; 185(3). PMID: 27124481    Free PMC article.
Review.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Cheng Xu, Yu-Pei Chen, +12 authors, Jun Ma.
BMJ, 2018 Nov 10; 363. PMID: 30409774    Free PMC article.
Highly Cited. Systematic Review.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
Molecular antagonism and plasticity of regulatory and inflammatory T cell programs.
Xuexian O Yang, Roza Nurieva, +10 authors, Chen Dong.
Immunity, 2008 Jul 01; 29(1). PMID: 18585065    Free PMC article.
Highly Cited.
Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.
Ya-Qing Li, Fang-Fang Liu, +3 authors, Li Fu.
PLoS One, 2013 Oct 15; 8(10). PMID: 24124553    Free PMC article.
Cutting edge: CTLA-4--B7 interaction suppresses Th17 cell differentiation.
Haiyan Ying, Lifen Yang, +5 authors, Jian Zhang.
J Immunol, 2010 Jul 06; 185(3). PMID: 20601598    Free PMC article.
OX40 costimulation turns off Foxp3+ Tregs.
Minh Diem Vu, Xiang Xiao, +6 authors, Xian Chang Li.
Blood, 2007 Jun 19; 110(7). PMID: 17575071    Free PMC article.
Highly Cited.
Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution.
Jonathan D Proto, Amanda C Doran, +10 authors, Ira Tabas.
Immunity, 2018 Oct 07; 49(4). PMID: 30291029    Free PMC article.
Highly Cited.
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
H-B Jie, N Gildener-Leapman, +4 authors, R L Ferris.
Br J Cancer, 2013 Oct 31; 109(10). PMID: 24169351    Free PMC article.
Highly Cited.
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
Sandra Demaria, Noriko Kawashima, +4 authors, Silvia C Formenti.
Clin Cancer Res, 2005 Feb 11; 11(2 Pt 1). PMID: 15701862
Highly Cited.
An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.
Yichen Tang, Xuejun Xu, +6 authors, Huaizhi Wang.
PLoS One, 2014 Mar 19; 9(3). PMID: 24637664    Free PMC article.
Highly Cited.
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.
Babak Baban, Phillip R Chandler, +4 authors, Andrew L Mellor.
J Immunol, 2009 Jul 29; 183(4). PMID: 19635913    Free PMC article.
Highly Cited.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Jianjun Gao, Neema Navai, +28 authors, Padmanee Sharma.
Nat Med, 2020 Oct 14; 26(12). PMID: 33046869
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.
Katharina Lahl, Christoph Loddenkemper, +7 authors, Tim Sparwasser.
J Exp Med, 2007 Jan 04; 204(1). PMID: 17200412    Free PMC article.
Highly Cited.
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Ahmad A Tarhini, Howard Edington, +9 authors, John M Kirkwood.
PLoS One, 2014 Feb 06; 9(2). PMID: 24498358    Free PMC article.
Highly Cited.
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.
Jingjie Chen, Shengnan Li, +8 authors, Yingying Tang.
World J Surg Oncol, 2020 Jul 06; 18(1). PMID: 32620130    Free PMC article.
Systematic Review.
Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors.
Danila Valmori, Caroline Raffin, Isabelle Raimbaud, Maha Ayyoub.
Proc Natl Acad Sci U S A, 2010 Oct 22; 107(45). PMID: 20962281    Free PMC article.
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
Xiaozhou Fan, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2014 Apr 02; 211(4). PMID: 24687957    Free PMC article.
Highly Cited.
Expression of Th17 cells in breast cancer tissue and its association with clinical parameters.
LiJuan Yang, YiXin Qi, +3 authors, BaoEn Shan.
Cell Biochem Biophys, 2011 Nov 15; 62(1). PMID: 22081436
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
R P Sutmuller, L M van Duivenvoorde, +6 authors, C J Melief.
J Exp Med, 2001 Sep 19; 194(6). PMID: 11560997    Free PMC article.
Highly Cited.
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Nils-Petter Rudqvist, Karsten A Pilones, +7 authors, Sandra Demaria.
Cancer Immunol Res, 2017 Nov 29; 6(2). PMID: 29180535    Free PMC article.
Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.
Alessia Angelin, Luis Gil-de-Gómez, +17 authors, Ulf H Beier.
Cell Metab, 2017 Apr 19; 25(6). PMID: 28416194    Free PMC article.
Highly Cited.
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
Bradley C Carthon, Jedd D Wolchok, +8 authors, Padmanee Sharma.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460488    Free PMC article.
Highly Cited.
Essential role of mitochondrial energy metabolism in Foxp3⁺ T-regulatory cell function and allograft survival.
Ulf H Beier, Alessia Angelin, +13 authors, Wayne W Hancock.
FASEB J, 2015 Feb 15; 29(6). PMID: 25681462    Free PMC article.
Highly Cited.
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
Mengnan He, Yan Chai, +6 authors, George F Gao.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978021    Free PMC article.
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.
Brian Kavanagh, Shaun O'Brien, +6 authors, Lawrence Fong.
Blood, 2008 Jun 05; 112(4). PMID: 18523152    Free PMC article.
Regulatory T cells in human disease and their potential for therapeutic manipulation.
Leonie S Taams, Donald B Palmer, +3 authors, Catherine M Hawrylowicz.
Immunology, 2006 Apr 25; 118(1). PMID: 16630018    Free PMC article.
Review.
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.
Yoshiki Mizukami, Koji Kono, +4 authors, Hideki Fujii.
Int J Cancer, 2008 Jan 29; 122(10). PMID: 18224687
Highly Cited.
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.
Lewis Z Shi, Ruoning Wang, +4 authors, Hongbo Chi.
J Exp Med, 2011 Jun 29; 208(7). PMID: 21708926    Free PMC article.
Highly Cited.
Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways.
Sarah R Jacobs, Catherine E Herman, +4 authors, Jeffrey C Rathmell.
J Immunol, 2008 Mar 21; 180(7). PMID: 18354169    Free PMC article.
Highly Cited.
Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Silvia C Formenti, Nils-Petter Rudqvist, +15 authors, Sandra Demaria.
Nat Med, 2018 Nov 07; 24(12). PMID: 30397353    Free PMC article.
Highly Cited.
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.
Valerie A Gerriets, Rigel J Kishton, +10 authors, Jeffrey C Rathmell.
Nat Immunol, 2016 Nov 01; 17(12). PMID: 27695003    Free PMC article.
Highly Cited.
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Emilio Sanseviero, Erin M O'Brien, +16 authors, Erica L Stone.
Cancer Immunol Res, 2019 Jun 27; 7(8). PMID: 31239316    Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Tina Cascone, William N William, +50 authors, Boris Sepesi.
Nat Med, 2021 Feb 20; 27(3). PMID: 33603241    Free PMC article.
CTLA-4 control over Foxp3+ regulatory T cell function.
Kajsa Wing, Yasushi Onishi, +5 authors, Shimon Sakaguchi.
Science, 2008 Oct 11; 322(5899). PMID: 18845758
Highly Cited.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.
Athanasios Kotsakis, Filippos Koinis, +5 authors, Eleni-Kyriaki Vetsika.
Sci Rep, 2016 Dec 16; 6. PMID: 27976733    Free PMC article.
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors.
Anli Zhang, Zhenhua Ren, +6 authors, Yang-Xin Fu.
Sci Transl Med, 2021 Aug 06; 13(605). PMID: 34349035
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.
Andrea Facciabene, Xiaohui Peng, +8 authors, George Coukos.
Nature, 2011 Jul 15; 475(7355). PMID: 21753853
Highly Cited.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.
Ilona Kryczek, Mousumi Banerjee, +11 authors, Weiping Zou.
Blood, 2009 May 28; 114(6). PMID: 19470694    Free PMC article.
Highly Cited.
IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer.
Ilona Kryczek, Ke Wu, +11 authors, Weiping Zou.
J Immunol, 2011 Mar 02; 186(7). PMID: 21357259
Highly Cited.
Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.
E C Halvorsen, M J Hamilton, +6 authors, K L Bennewith.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471618    Free PMC article.
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778278    Free PMC article.
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, +24 authors, Alessandro Testori.
N Engl J Med, 2016 Oct 09; 375(19). PMID: 27717298    Free PMC article.
Highly Cited.
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, +15 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2018 Mar 28; 115(15). PMID: 29581255    Free PMC article.
Highly Cited.
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy.
David Zahavi, Dalal AlDeghaither, Allison O'Connell, Louis M Weiner.
Antib Ther, 2018 Jun 24; 1(1). PMID: 33928217    Free PMC article.
Review.
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.
Ping-Chih Ho, Jessica Dauz Bihuniak, +15 authors, Susan M Kaech.
Cell, 2015 Sep 01; 162(6). PMID: 26321681    Free PMC article.
Highly Cited.
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Yannick Bulliard, Rose Jolicoeur, +3 authors, Jennifer L Brogdon.
Immunol Cell Biol, 2014 Apr 16; 92(6). PMID: 24732076
Highly Cited.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, +17 authors, Thierry André.
J Clin Oncol, 2018 Jan 23; 36(8). PMID: 29355075
Highly Cited.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Properties of mouse and human IgG receptors and their contribution to disease models.
Pierre Bruhns.
Blood, 2012 Apr 27; 119(24). PMID: 22535666
Highly Cited. Review.
Metabolic Adaptation of Human CD4+ and CD8+ T-Cells to T-Cell Receptor-Mediated Stimulation.
Nicholas Jones, James G Cronin, +7 authors, Nigel J Francis.
Front Immunol, 2017 Nov 25; 8. PMID: 29170670    Free PMC article.
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Pia Kvistborg, Daisy Philips, +13 authors, Ton N Schumacher.
Sci Transl Med, 2014 Sep 19; 6(254). PMID: 25232180
Highly Cited.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
Benjamin Kuehnemuth, Ignazio Piseddu, +8 authors, David Anz.
BMC Cancer, 2018 Dec 24; 18(1). PMID: 30572845    Free PMC article.
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.
Elda Righi, Satoshi Kashiwagi, +14 authors, Mark C Poznansky.
Cancer Res, 2011 Jul 12; 71(16). PMID: 21742774    Free PMC article.
Highly Cited.
CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Alan L Chang, Jason Miska, +13 authors, Maciej S Lesniak.
Cancer Res, 2016 Aug 18; 76(19). PMID: 27530322    Free PMC article.
Highly Cited.
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.
Saman Maleki Vareki.
J Immunother Cancer, 2018 Dec 28; 6(1). PMID: 30587233    Free PMC article.
Highly Cited.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate Kelley, Bruno Sangro, +21 authors, Ghassan K Abou-Alfa.
J Clin Oncol, 2021 Jul 23; 39(27). PMID: 34292792    Free PMC article.
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28.
A Hutloff, A M Dittrich, +4 authors, R A Kroczek.
Nature, 1999 Feb 04; 397(6716). PMID: 9930702
Highly Cited.
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +26 authors, F Stephen Hodi.
J Clin Oncol, 2021 Nov 25; 40(2). PMID: 34818112    Free PMC article.
Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Francesco Marangoni, Ademi Zhakyp, +10 authors, Thorsten R Mempel.
Cell, 2021 Jun 23; 184(15). PMID: 34157302    Free PMC article.
ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.
J L Riley, P J Blair, +4 authors, C H June.
J Immunol, 2001 Apr 06; 166(8). PMID: 11290772
Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer.
Alexander Pedroza-Gonzalez, Cornelis Verhoef, +5 authors, Dave Sprengers.
Hepatology, 2012 Aug 23; 57(1). PMID: 22911397
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.
Daniel Hirschhorn-Cymerman, Gabrielle A Rizzuto, +6 authors, Alan N Houghton.
J Exp Med, 2009 May 06; 206(5). PMID: 19414558    Free PMC article.
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.
Hans J P M Koenen, Ruben L Smeets, +3 authors, Irma Joosten.
Blood, 2008 Jul 12; 112(6). PMID: 18617638
Highly Cited.
Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells.
Julia Krombach, Roman Hennel, +12 authors, Kirsten Lauber.
Oncoimmunology, 2018 Dec 14; 8(1). PMID: 30546963    Free PMC article.
Turning cold tumors into hot tumors by improving T-cell infiltration.
Yuan-Tong Liu, Zhi-Jun Sun.
Theranostics, 2021 Apr 17; 11(11). PMID: 33859752    Free PMC article.
Review.
The relative change in regulatory T cells / T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients.
Tong Xu, Jiezhen Lu, Hanxiang An.
Oncotarget, 2018 Jan 10; 8(65). PMID: 29312592    Free PMC article.
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Tihui Fu, Qiuming He, Padmanee Sharma.
Cancer Res, 2011 Jun 29; 71(16). PMID: 21708958
Isotype selection for antibody-based cancer therapy.
N Vukovic, A van Elsas, J S Verbeek, D M W Zaiss.
Clin Exp Immunol, 2020 Nov 07; 203(3). PMID: 33155272    Free PMC article.
Review.
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Pawel Muranski, Andrea Boni, +14 authors, Nicholas P Restifo.
Blood, 2008 Mar 21; 112(2). PMID: 18354038    Free PMC article.
Highly Cited.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.
Ryan D Michalek, Valerie A Gerriets, +6 authors, Jeffrey C Rathmell.
J Immunol, 2011 Feb 15; 186(6). PMID: 21317389    Free PMC article.
Highly Cited.
Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients.
Dan Wang, Weina Yu, +13 authors, Yi Zhang.
J Hematol Oncol, 2020 Jun 07; 13(1). PMID: 32503584    Free PMC article.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.
Marie Tosolini, Amos Kirilovsky, +8 authors, Jérôme Galon.
Cancer Res, 2011 Feb 10; 71(4). PMID: 21303976
Highly Cited.
Metabolic modeling of single Th17 cells reveals regulators of autoimmunity.
Allon Wagner, Chao Wang, +23 authors, Nir Yosef.
Cell, 2021 Jul 04; 184(16). PMID: 34216539    Free PMC article.
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Emanuela Romano, Monika Kusio-Kobialka, +7 authors, Daniel E Speiser.
Proc Natl Acad Sci U S A, 2015 Apr 29; 112(19). PMID: 25918390    Free PMC article.
Highly Cited.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, +18 authors, Chiun Hsu.
JAMA Oncol, 2020 Oct 02; 6(11). PMID: 33001135    Free PMC article.
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
M F Krummel, J P Allison.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676074    Free PMC article.
Highly Cited.
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.
Bin Shang, Yao Liu, Shu-juan Jiang, Yi Liu.
Sci Rep, 2015 Oct 16; 5. PMID: 26462617    Free PMC article.
Highly Cited. Systematic Review.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, +23 authors, Suresh S Ramalingam.
N Engl J Med, 2019 Sep 29; 381(21). PMID: 31562796
Highly Cited.
CTLA-4 ligation blocks CD28-dependent T cell activation.
T L Walunas, C Y Bakker, J A Bluestone.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676075    Free PMC article.
Highly Cited.
Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
Emily M Schmidt, Chun Jing Wang, +7 authors, Lucy S K Walker.
J Immunol, 2008 Dec 26; 182(1). PMID: 19109158
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
Danielle M Lussier, Elise Alspach, +10 authors, Robert D Schreiber.
Proc Natl Acad Sci U S A, 2021 Jun 09; 118(24). PMID: 34099555    Free PMC article.
CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function.
Tanya Girard, Denis Gaucher, +2 authors, Rafick-Pierre Sékaly.
Immunol Lett, 2014 May 23; 161(1). PMID: 24845157
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.
Monika Semmrich, Jean-Baptiste Marchand, +15 authors, Björn Frendéus.
J Immunother Cancer, 2022 Jan 22; 10(1). PMID: 35058324    Free PMC article.
T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
Natalia Martin-Orozco, Pawel Muranski, +7 authors, Chen Dong.
Immunity, 2009 Nov 03; 31(5). PMID: 19879162    Free PMC article.
Highly Cited.
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Ajay V Maker, Peter Attia, Steven A Rosenberg.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301685    Free PMC article.
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Yan Zhang, Xuexiang Du, +9 authors, Yang Liu.
Cell Res, 2019 Jul 04; 29(8). PMID: 31267017    Free PMC article.
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation.
Kathryn E Beckermann, Rachel Hongo, +12 authors, Jeffrey C Rathmell.
JCI Insight, 2020 Aug 21; 5(16). PMID: 32814710    Free PMC article.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Danbee Ha, Atsushi Tanaka, +10 authors, Shimon Sakaguchi.
Proc Natl Acad Sci U S A, 2018 Dec 28; 116(2). PMID: 30587582    Free PMC article.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.
Aras Toker, Linh T Nguyen, +14 authors, Pamela S Ohashi.
Clin Cancer Res, 2018 Aug 02; 24(22). PMID: 30065096
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Eva Schlecker, Ana Stojanovic, +4 authors, Adelheid Cerwenka.
J Immunol, 2012 Nov 16; 189(12). PMID: 23152559
Highly Cited.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
R Perets, J Bar, +17 authors, B C Cho.
Ann Oncol, 2020 Dec 05; 32(3). PMID: 33276076
Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation.
Chunxia Chen, Emily A Rowell, +2 authors, Andrew D Wells.
J Biol Chem, 2006 Oct 10; 281(48). PMID: 17028180
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Silvia Piconese, Barbara Valzasina, Mario P Colombo.
J Exp Med, 2008 Mar 26; 205(4). PMID: 18362171    Free PMC article.
Highly Cited.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Spencer C Wei, Nana-Ama A S Anang, +8 authors, James P Allison.
Proc Natl Acad Sci U S A, 2019 Oct 23; 116(45). PMID: 31636208    Free PMC article.
ICOS signal facilitates Foxp3 transcription to favor suppressive function of regulatory T cells.
Qianmei Chen, Lijun Mo, +5 authors, Zhiming Hu.
Int J Med Sci, 2018 Jun 19; 15(7). PMID: 29910670    Free PMC article.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
Erika von Euw, Thinle Chodon, +4 authors, Antoni Ribas.
J Transl Med, 2009 May 22; 7. PMID: 19457253    Free PMC article.
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Anne Månsson Kvarnhammar, Niina Veitonmäki, +16 authors, Peter Ellmark.
J Immunother Cancer, 2019 Apr 13; 7(1). PMID: 30975201    Free PMC article.
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Anand Rotte.
J Exp Clin Cancer Res, 2019 Jun 15; 38(1). PMID: 31196207    Free PMC article.
Highly Cited. Review.
Modulation of tryptophan catabolism by regulatory T cells.
Francesca Fallarino, Ursula Grohmann, +7 authors, Paolo Puccetti.
Nat Immunol, 2003 Oct 28; 4(12). PMID: 14578884
Highly Cited.
Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer.
Takeshi Iida, Makoto Iwahashi, +9 authors, Hiroki Yamaue.
Oncol Rep, 2011 Mar 04; 25(5). PMID: 21369705
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.
Barbara Valzasina, Cristiana Guiducci, +3 authors, Mario P Colombo.
Blood, 2004 Dec 14; 105(7). PMID: 15591118
Highly Cited.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Omid Hamid, Henrik Schmidt, +9 authors, David Berman.
J Transl Med, 2011 Nov 30; 9. PMID: 22123319    Free PMC article.
Highly Cited.
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Christian U Blank, Elisa A Rozeman, +21 authors, Ton N Schumacher.
Nat Med, 2018 Oct 10; 24(11). PMID: 30297911
Highly Cited.
Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion.
Zhi-Jian Ye, Qiong Zhou, +5 authors, Huan-Zhong Shi.
J Immunol, 2010 Oct 19; 185(10). PMID: 20952674
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells.
Hidenori Takahashi, Muneo Numasaki, Michael T Lotze, Hidetada Sasaki.
Immunol Lett, 2005 Apr 30; 98(2). PMID: 15860217
Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer.
Gareth Betts, Emma Jones, +9 authors, Andrew Godkin.
Gut, 2011 Dec 31; 61(8). PMID: 22207629    Free PMC article.
The diverse functions of the PD1 inhibitory pathway.
Arlene H Sharpe, Kristen E Pauken.
Nat Rev Immunol, 2017 Oct 11; 18(3). PMID: 28990585
Highly Cited. Review.
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Zeynep Eroglu, Dae Won Kim, +9 authors, Antoni Ribas.
Eur J Cancer, 2015 Sep 15; 51(17). PMID: 26364516    Free PMC article.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Tumor microenvironments direct the recruitment and expansion of human Th17 cells.
Xinming Su, Jian Ye, +3 authors, Guangyong Peng.
J Immunol, 2009 Dec 23; 184(3). PMID: 20026736
Highly Cited.
Mitochondrial complex III is essential for suppressive function of regulatory T cells.
Samuel E Weinberg, Benjamin D Singer, +10 authors, Navdeep S Chandel.
Nature, 2019 Jan 11; 565(7740). PMID: 30626970    Free PMC article.
Highly Cited.
Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Jun Mitsui, Hiroyoshi Nishikawa, +9 authors, Hiroshi Shiku.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460483